New ABL1 Kinase Domain Mutations in BCR::ABL1‐Positive Acute Lymphoblastic Leukemia
ABSTRACT Background Since the development of the first‐generation Tyrosine Kinase Inhibitor (TKI), it has played a crucial role in the treatment of BCR::ABL1‐positive acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). However, ABL1 kinase domain (ABL1 KD) mutations confer resista...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Wiley
2024-10-01
|
| Ráidu: | Cancer Medicine |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.1002/cam4.70317 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|